Paul Edward Kelly, Director at RELMADA THERAPEUTICS, INC. (RLMD), bought 373,483 shares at $0.90 ($296K) on 2018-10-12, disclosed to the SEC on 2018-10-19.
Open-market purchase of $296k RLMD by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.90 | 150,000 | $135K | 45.6% |
| 2 | $0.72 | 223,483 | $161K | 54.4% |
| Total | $0.79 avg | 373,483 | $296K | 100% |
| Filing → |
| RLMD | BUY | 2024-09-11 | $65K | — | Filing → |
| RLMD | SELL | 2022-04-05 | $300K | — | Filing → |
| RLMD | SELL | 2021-03-11 | $357K | — | Filing → |